Crossmark

Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function

Crossref DOI link: https://doi.org/10.1186/s44348-024-00043-0

Published Online: 2025-01-13

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jeon, Kina

Jang, Shin Yi

Lee, You-Bin

Kim, Jihoon

Kim, Darae

Chang, Sung-A

Park, Sung-Ji

Lee, Sang-Chol

Park, Seung Woo

Lee, Moon-Kyu

Kim, Eun Kyoung

Hur, Kyu Yeon
Funding

Funding for this research was provided by:

Korean Society of Echocardiography,South Korea (KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901, KSER-201901)
License Information

Text and Data Mining valid from 2025-01-13

Version of Record valid from 2025-01-13
More Information

Article History

Received: 29 June 2024

Accepted: 2 December 2024

First Online: 13 January 2025

Declarations

:

: The studies involving human participants were reviewed and approved by the Institutional Review Board of Samsung Medical Center (No. SMC 2018–05-116–004, SMC 2024–05-032–001). The patients/participants provided written informed consent to participate in this study. The studies and/or procedures performed for this article that involved human participants were consistent with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below